{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:57:41Z","timestamp":1792785461588,"version":"4.5.0"},"reference-count":69,"publisher":"Informa UK Limited","issue":"17","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Institute of Health","award":["T32CA251072"],"award-info":[{"award-number":["T32CA251072"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,7,15]]},"DOI":"10.1080\/14796694.2025.2513848","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:51:49Z","timestamp":1749707509000},"page":"2143-2153","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer"],"prefix":"10.1080","volume":"21","author":[{"given":"Jordyn","family":"Silverstein","sequence":"first","affiliation":[{"name":"University of California","place":["Los Angeles, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Smick","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Johnson","sequence":"additional","affiliation":[{"name":"University of California","place":["Los Angeles, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried E","family":"Konecny","sequence":"additional","affiliation":[{"name":"University of California","place":["Los Angeles, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390772"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.11.3678"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3244"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/GCO.0000000000001002"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2024.101450"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2018.06.018"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10166"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00086-8"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30279-6"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_288015"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3312"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01771"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.6735"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00470-8"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-19-0582"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.11.020"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2011.11.010"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.2596"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-1095"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00850-2"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2009.03.023"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102546"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004924"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31110522"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15937"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/11795549231187264"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16250"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30736"},{"key":"e_1_3_5_34_1","unstructured":"Postmarketing requirements and commitments: searchable database [Internet]. [cited 2025 Apr 1]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/pmc\/index.cfm?StartRow=1&StepSize=1&Paging=Yes"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.07.017"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01900"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.01.020"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy285.157"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.017"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169"},{"key":"e_1_3_5_41_1","unstructured":"Expert discusses the safety and efficacy of mirvetuximab soravtansine in ovarian cancer following FORWARD I findings [internet]. Target Oncol. 2019 [cited 2024 Sep 12]. Available from: https:\/\/www.targetedonc.com\/view\/expert-discusses-the-safety-and-efficacy-of-mirvetuximab-soravtansine-in-ovarian-cancer-following-forward-i-findings"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.01.037"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(22)01521-9"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.5504"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.01.045"},{"key":"e_1_3_5_46_1","unstructured":"Arend R. Single-arm phase II study of carboplatin and mirvetuximab soravtansine in first-line treatment of patients receiving neoadjuvant chemotherapy with advanced-stage ovarian fallopian tube or primary peritoneal cancer who are folate receptor \u03b1 positive [internet]. Report No.: nCT04606914. Available from clinicaltrials.gov; 2023 Nov [cited 2023 Dec 31]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04606914"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5618"},{"key":"e_1_3_5_48_1","unstructured":"Mirvetuximab Soravtansine (MIRV) with carboplatin in second-line treatment of folate receptor alpha (FR\u03b1) expressing platinum-sensitive epithelial ovarian cancer - NCI. 2016 [cited 2024 Dec 4]. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/clinical-trials\/search\/v?id=NCT05456685"},{"key":"e_1_3_5_49_1","unstructured":"University of Colorado Denver. A phase II evaluation of maintenance therapy combination mirvetuximab soravtansine and olaparib in recurrent platinum sensitive ovarian peritoneal and fallopian tube cancer [internet]. Report No.: nCT05887609. Available from clinicaltrials.gov; 2024 May [cited 2023 Dec 31]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05887609"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5622"},{"key":"e_1_3_5_51_1","volume-title":"Presented at: 2024 ESMO Congress","author":"Secord AA","year":"2024","unstructured":"Secord AA, Corr BR, Lewin S, et al. Mirvetuximab soravtansine (MIRV) in recurrent platinum-sensitive ovarian cancer (PSOC) with high folate receptor-alpha (FR\u03b1) expression: results from the PICCOLO trial. In: Presented at: 2024 ESMO Congress; Barcelona, Spain; 2024 Sep 13\u201317. Abstract 718MO."},{"key":"e_1_3_5_52_1","article-title":"The efficacy and safety of mirvetuximab soravtansine in FR\u03b1-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase 2 PICCOLO trial","author":"Secord AA","year":"2024","unstructured":"Secord AA, Lewin SN, Murphy CG, et al. The efficacy and safety of mirvetuximab soravtansine in FR\u03b1-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase 2 PICCOLO trial. Ann Of Oncol [Internet]. 2024 Nov 29 [cited 2025 Jan 3]. Available from: https:\/\/www.annalsofoncology.org\/article\/S0923-7534(24)04948-2\/fulltext","journal-title":"Ann Of Oncol"},{"key":"e_1_3_5_53_1","unstructured":"McNulty R. NCCN guidelines update adds mirvetuximab soravtansine plus Bevacizumab for FR\u03b1-expressing platinum-sensitive ovarian cancer. AJMC. 2024 Jan 19;30:SP113\u2013SP113."},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2024.101574"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101141"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101155"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101148"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.10.013"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00097"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2024.101486"},{"issue":"1","key":"e_1_3_5_61_1","article-title":"360\u00a0health-related quality of life in patients with FR\u03b1 positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine vs. investigator\u2019s choice chemotherapy: analysis from the phase 3 MIRASOL trial","volume":"34","author":"Garcia YG","year":"2024","unstructured":"Garcia YG, Gorp TV, Konecny GE, et al. 360\u00a0health-related quality of life in patients with FR\u03b1 positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine vs. investigator\u2019s choice chemotherapy: analysis from the phase 3 MIRASOL trial. Int J Gynecologic Cancer [Internet]. 2024 Mar 1 [cited 2024 Dec 4];34(Suppl 1). Available from: https:\/\/ijgc.bmj.com\/content\/34\/Suppl_1\/A34","journal-title":"Int J Gynecologic Cancer"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.023"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0991"},{"key":"e_1_3_5_64_1","unstructured":"EMA accepts marketing authorization application for mirvetuximab soravtansine in FR\u03b1+ platinum-resistant ovarian cancer [internet]. AJMC. 2023 [cited 2024 Nov 19]. Available from: https:\/\/www.ajmc.com\/view\/ema-accepts-marketing-authorization-application-for-mirvetuximab-soravtansine-in-fr-platinum-resistant-ovarian-cancer"},{"key":"e_1_3_5_65_1","unstructured":"Elahere. European Medicines Agency (EMA) [Internet]. 2024 [cited 2024 Nov 19]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elahere"},{"key":"e_1_3_5_66_1","unstructured":"AbbVie Receives European Commission approval of ELAHERE\u00ae (mirvetuximab soravtansine) for the treatment of platinum-resistant ovarian cancer [internet]. AbbVie news center. [cited 2024 Nov 19]. Available from: https:\/\/news.abbvie.com\/2024-11-18-AbbVie-Receives-European-Commission-Approval-of-ELAHERE-R-mirvetuximab-soravtansine-for-the-Treatment-of-Platinum-Resistant-Ovarian-Cancer"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390094"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0635-y"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.06.008"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.08.015"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2513848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:19:17Z","timestamp":1763043557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2513848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":69,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,7,15]]}},"alternative-id":["10.1080\/14796694.2025.2513848"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2513848","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-01-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}